0000000000548052

AUTHOR

Celina Benavente

showing 3 related works from this author

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

2020

PETHEMA, HOVON, PALG, GATLA cooperative groups.

MaleMultivariate analysisOverweightTOXICITYBody Mass Index0302 clinical medicineLeukemia Promyelocytic AcuteRecurrenceAcute promyelocytic leukemiaAntineoplastic Combined Chemotherapy ProtocolsDIFFERENTIATION SYNDROMEOutcomeAged 80 and overAIDA protocolMercaptopurineMortality rateIncidence (epidemiology)HematologyGeneral MedicineMiddle AgedPrognosisTreatment OutcomeVincristinePopulation Surveillance030220 oncology & carcinogenesisFemalemedicine.symptomUnderweightAdultmedicine.medical_specialtyAdolescentACUTE MYELOID-LEUKEMIADIAGNOSISYoung Adult03 medical and health sciencesInternal medicinemedicineAsparaginaseHumansObesityRisk factorAgedRESPONSE CRITERIAOVERWEIGHTbusiness.industrynutritional and metabolic diseasesANTHRACYCLINEmedicine.diseaseObesityRISK-ADAPTED TREATMENTMethotrexateTRANS-RETINOIC ACIDPrednisonebusinessBody mass index030215 immunologyEuropean Journal of Haematology
researchProduct

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

2020

INTRODUCTION Coronavirus disease 2019 (COVID-19) caused by SARS-CoV2 virus is thought to be more severe in patients with prior hematological diseases. There is evidence suggesting that hematological patients are particularly vulnerable and have a higher risk of developing severe events, with higher mortality rate than general population. However, the available data are limited, and prognostic factors at admission still remain unclear. With this background, our aims were to analyze the impact of hematological diseases and their therapy on the COVID-19 severity and to identify clinical and biological risk factors to predict the outcome in these patients. METHODS We carried out a multicenter …

medicine.medical_specialtyeducation.field_of_studybusiness.industryMortality rateImmunologyPopulation203.Lymphocytes Lymphocyte Activation and Immunodeficiency including HIV and Other InfectionsRetrospective cohort studyCell BiologyHematologyDiseasemedicine.diseaseBiochemistryComorbidityMulticenter studyInternal medicineIntensive caremedicineIn patienteducationbusinessBlood
researchProduct

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

2018

Treatment outcome in older patients with acute promyelocytic leukemia (APL) is lower compared with younger patients, mainly because of a higher induction death rate and postremission non-relapse mortality (NRM). This prompted us to design a risk-and age-adapted protocol (Programa Espanol de Tratamientos en Hematologia (PETHEMA)/HOVON LPA2005), with dose reduction of consolidation chemotherapy. Patients aged >= 60 years reported to the PETHEMA registry and were treated with all-trans retinoic acid (ATRA) plus anthracycline-based regimens according to three consecutive PETHEMA trials that were included. We compared the long-term outcomes of the LPA2005 trial with the preceding PETHEMA tria…

MaleAcute promyelocytic leukemiaCancer Researchmedicine.medical_specialtyAnthracyclinemedicine.medical_treatmentTretinoinACUTE MYELOID-LEUKEMIADisease-Free Survival03 medical and health sciencesPROGNOSTIC-FACTORS0302 clinical medicineLeukemia Promyelocytic AcuteOlder patientsRecurrenceRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesCumulative incidenceELDERLY-PATIENTSAgedCONSOLIDATIONChemotherapyMONOCHEMOTHERAPYbusiness.industryRemission InductionConsolidation ChemotherapyHematologyMiddle Agedmedicine.diseaseCOMPETING RISKSARSENIC TRIOXIDESurgeryRISK-ADAPTED TREATMENTRegimenLeukemiaTreatment OutcomeTRANS-RETINOIC ACIDOncology030220 oncology & carcinogenesisPETHEMA GROUPFemalebusiness030215 immunologyLeukemia
researchProduct